Last reviewed · How we verify

NCT04378608

Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4

Completed Phase 1, PHASE2 Last updated 12 May 2020
What this trial tests

Phase 1, PHASE2 trial testing OBV/PTV/r) ± ribavirin (RBV) in Hepatitis C Virus Infection in 100 participants. Completed in 8 September 2017.

Timeline
5 January 2017
Primary endpoint
8 September 2017
8 September 2017

Quick facts

Lead sponsorBeni-Suef University
PhasePhase 1, PHASE2
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment100
Start date5 January 2017
Primary completion8 September 2017
Estimated completion8 September 2017

Drugs / interventions tested

Conditions studied

Sponsor

Beni-Suef University

Who can join

Adults 18 to 70, any sex, with Hepatitis C Virus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the investigators was to delineate the efficacy and safety of Ombitasvir, paritaprevir with ritonavir (OBV/PTV/r) plus ribavirin (RBV) on chronic HCV GT4 Egyptian naïve patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hepatitis C Virus Infection

Currently open trials in the same condition.

Other Beni-Suef University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04378608.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing